Actionable news
All posts from Actionable news
Actionable news in MDVN: Medivation, Inc.,

Sanofi Wants To Acquire Medivation For $52.50 Per Share

Trade with confidence. Are you a professional trader? Be the first to get the alert with Benzinga Pro's real-time newsfeed and audio squawk and never miss an opportunity again.
Don't miss the chance to try it FREE today.

Medivation, Inc. NASDAQ:MDVN, Sanofi NYSE:SNY - Sanofi Wants To Acquire Medivation For $52.50 Per Share

Sanofi SA (ADR) SNY 1.25% announced on Thursday that it has sent a letter to Medivation Inc MDVN 8.65% in which it confirmed an offer to acquire the company for $52.50 per share was proposed on April 15 and initial discussions regarding a merger were held in late March.

Shares of Medivation spiked higher by more than 7 percent Thursday morning and traded at $56.01.

The proposed buyout price implies a $9.3 billion valuation and represents a 50 percent premium to Medivation's two-month volume weighted average price prior to takeover rumors surfacing.

According to Sanofi, an acquisition of Medivation would create a "compelling strategic and financial opportunity to drive significant value for the respective companies' shareholders, employees, patients and caregivers."

Sanofi added that it has a strong track record of integrating acquired companies and Medivation would benefit from its already existing global capabilities, resources, internal pipeline of assets and complementary product offerings.

"Last November, Sanofi outlined our mid-term strategy which includes rebuilding our position in oncology, one of the largest and fastest growing therapeutic areas in the biopharmaceutical sector," said Sanofi Chief Executive Officer Olivier Brandicourt. "With Medivation's best-in-class offerings in prostate cancer, we believe a combination would benefit patients and, at the same time, generate value for shareholders of both companies."

© 2016 Benzinga does not provide investment advice. All rights reserved.